Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | OCT-A: a diagnostic tool in multiple sclerosis

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, describes the significance
optical coherence tomography angiography (OCT-A) in multiple sclerosis (MS). OCT-A s a new imaging method used to quantify retinal vascular density in neurodegenerative and inflammatory diseases, but there are very few reports using OCT-A in patients with MS. A pilot study was conducted to investigate vascular changes and vessel density detected by OCT-A in MS patients with and without neuritis. It was observed that patients with optic neuritis had alterations and less vascularization in the retina compared to patients without previous neuritis. OCT-A is an important tool to assess the retinal vascular network, and retinal vessel density could represent a novel early biomarker to monitor the MS burden. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


C Oreja-Guevara has received honoraria for speaking and serving on advisory boards from Biogen Idec., F. Hoffmann-La Roche Ltd, Sanofi-Genzyme, Merck, Janssen, BMS, Novartis, and Teva.